Biotech Values

[BioSpecialist]

IGXT.OB..The next VNDA !!!!


This stock is vertualy unknown to investors. If you do your homework, you will clearly see that this stock will rise rapidly as soon as it gets noticed.

This is a real sleeper !!!! Please do your own Research .


Intelgenx Technologies (IGXT.OB)

MarketCap : 10,3 Mio US$
Price : 0,51 $

Shares Out : 20,85 M


Check out their fantastic Pipeline !
http://www.intelgenx.com/products/pipeline.html


Insider activity
http://finance.yahoo.com/q/it?s=IGXT.OB



RECENT OPERATIONAL HIGHLIGHTS ( May 2009)

- Filed NDA with U.S. Food and Drug Administration (FDA) - IntelGenx and Cary Pharmaceuticals filed a New Drug Application (NDA) under CFR 21 section 505(b)(2) for the CPI-300 antidepressant. CPI-300 is a new strength of a leading antidepressant that will provide a more convenient dosing option to patients with major depressive disorder ("MDD").

IntelGenx and Cary Pharmaceuticals entered into a Collaborative Agreement in November 2007 to jointly develop and commercialize CPI-300 using IntelGenx's proprietary oral delivery technology. Under the terms of the Collaborative Agreement, IntelGenx raised $2 million in March 2008 to fund completion of the product development and Cary Pharmaceuticals acted as the applicant for the submission of the NDA. Upon commercialization of the product, IntelGenx and Cary Pharmaceuticals would share profits.

- Earned Royalty Revenue for the first time in Company's History - IntelGenx earned royalty revenues of approximately $42.9 thousand in Q1, 2009 in respect of commercial activities in November and December 2008. Royalty revenues were earned from commercialization of the first product fully-developed by the Company, a prenatal multivitamin supplement marketed as Gesticare® in the USA, which was commercialized in November 2008.

- Announced Positive Phase 1(b) Clinical Study Results for Relivar - IntelGenx and Cannasat Therapeutics Inc., announced positive results for the Phase 1(b) clinical trial of Relivar, the first buccal dronabinol drug delivery product, which was developed using IntelGenx' proprietary AdVersa buccal delivery technology. Buccal delivery allows for drug absorption from the mouth directly into the bloodstream as opposed to the intestinal tract absorption seen with oral tablet technologies.

In this clinical trial, Relivar delivered twice the amount of dronabinol into the bloodstream versus the reference drug Marinol (as measured by AUC) with no increase in adverse events.

- Signed New Partnership Agreement with European Pharmaceutical Company - IntelGenx announced a new partnership with Circ Pharma Limited, a specialty pharmaceutical company based in Ireland, to develop and commercialize a novel drug for the treatment of hyperlipidemia.

In accordance with the Agreement, IntelGenx will be responsible for the formulation, manufacture and supply to Circ Pharma of the drug product. Circ Pharma will be responsible for commercialization of the product. Circ Pharma will fund the development of the product and IntelGenx will receive royalties from the product's sales.


In announcing the results, Horst Zerbe, President and Chief Executive Officer of IntelGenx, said:

"In the first few months of 2009 IntelGenx has already achieved a number of notable firsts in our corporate history: the 505(b)(2) NDA for the CPI-300 antidepressant was filed, and, for the first time, we earned sales and manufacturing royalties on the first